WASHINGTON — The Trump administration is exploring policy changes that could eventually lower the prices Medicare beneficiaries pay at the pharmacy counter.
Although it’s only a small, initial step in that direction, it’s one of the first signals of how the Trump administration is trying to deliver on the president’s promises to lower prescription drug prices.
The proposal likely won’t directly affect the bottom line of drug manufacturers President Trump has repeatedly accused of “getting away with murder” — indeed, by some accounts, they could make more money under the change. Instead, the proposal will more directly affect insurance companies and pharmacy benefit managers, or PBMs — long blamed by pharmaceutical manufacturers for high prices.
About the Author Reprints
